Argo assisted iTeos Therapeutics in its USD 75 million Series B Financing

Home News Argo assisted iTeos Therapeutics in its USD 75 million Series B Financing

Argo assisted iTeos Therapeutics, a Belgian biotechnology company developing novel cancer immunotherapies, in its USD 75 million Series B Financing led for the new investors by MPM Capital, with participation from HBM Partners, 6 Dimensions Capital and Curative Ventures. Existing investors Fund+, VIVES II and SRIW invested as well alongside SFPI.